A Phase 2b Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-2)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Ulcerative Colitis
  • Age: Between 18 Year(s) - 85 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Has a body mass index (BMI) within the range of 18.0 and 33.0 kg/m2 (inclusive).
    2. Participants must comply with contraception requirements per study guidelines.

You may not be eligible for this study if the following are true:

    1. Diagnosed with indeterminate colitis, microscopic colitis, ischemic colitis, radiation colitis, or Crohn's disease or has clinical findings suggestive of Crohn's disease
    2. Has current evidence of un-resected colonic dysplasia or un-

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.